IL130143A0 - Humanized anti-CD11a antibodies - Google Patents

Humanized anti-CD11a antibodies

Info

Publication number
IL130143A0
IL130143A0 IL13014397A IL13014397A IL130143A0 IL 130143 A0 IL130143 A0 IL 130143A0 IL 13014397 A IL13014397 A IL 13014397A IL 13014397 A IL13014397 A IL 13014397A IL 130143 A0 IL130143 A0 IL 130143A0
Authority
IL
Israel
Prior art keywords
humanized anti
cd11a antibodies
cd11a
antibodies
humanized
Prior art date
Application number
IL13014397A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL130143A0 publication Critical patent/IL130143A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL13014397A 1996-11-27 1997-10-20 Humanized anti-CD11a antibodies IL130143A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75720596A 1996-11-27 1996-11-27
PCT/US1997/019041 WO1998023761A1 (fr) 1996-11-27 1997-10-20 ANTICORPS ANTI-CD11a HUMANISES

Publications (1)

Publication Number Publication Date
IL130143A0 true IL130143A0 (en) 2000-06-01

Family

ID=25046834

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13014397A IL130143A0 (en) 1996-11-27 1997-10-20 Humanized anti-CD11a antibodies
IL130143A IL130143A (en) 1996-11-27 1999-05-26 Humanized antibodies to 11CDa that include a variable region in which non-human antibody amino acids
IL175583A IL175583A0 (en) 1996-11-27 2006-05-11 HUMANIZED ANTI-CD11a ANTIBODIES CONTAINING A VARIABLE DOMAIN HAVING AMINO ACIDS FROM A NON-HUMAN ANTIBODY

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL130143A IL130143A (en) 1996-11-27 1999-05-26 Humanized antibodies to 11CDa that include a variable region in which non-human antibody amino acids
IL175583A IL175583A0 (en) 1996-11-27 2006-05-11 HUMANIZED ANTI-CD11a ANTIBODIES CONTAINING A VARIABLE DOMAIN HAVING AMINO ACIDS FROM A NON-HUMAN ANTIBODY

Country Status (17)

Country Link
EP (2) EP1516629B1 (fr)
JP (2) JP3778945B2 (fr)
KR (1) KR100532178B1 (fr)
AR (1) AR008919A1 (fr)
AT (1) ATE267257T1 (fr)
AU (1) AU731817C (fr)
CA (1) CA2272842C (fr)
DE (3) DE122004000047I2 (fr)
DK (2) DK0941344T3 (fr)
ES (1) ES2221045T3 (fr)
FR (1) FR04C0028I2 (fr)
IL (3) IL130143A0 (fr)
LU (1) LU91122I2 (fr)
NL (1) NL300163I2 (fr)
PT (1) PT941344E (fr)
WO (1) WO1998023761A1 (fr)
ZA (1) ZA979599B (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
EP1950300A3 (fr) 1998-11-18 2011-03-23 Genentech, Inc. Variantes d'anticorps avec une affinité de liaison plus élevée en comparaison aux anticorps parents
DE69938054T2 (de) 1998-11-18 2009-02-12 Genentech, Inc., South San Francisco Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
IL145480A0 (en) * 1999-03-19 2002-06-30 Genentech Inc Treatment of lfa-1 associated disorders with increasing doses of lfa-1
PT1237575E (pt) * 1999-12-14 2008-11-17 Genentech Inc Antagonista de tnf-alfa e antagonista de lfa-1 para tratar a artrite reumatóide
US7560275B2 (en) 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
US7575921B2 (en) 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
WO2001051084A1 (fr) * 2000-01-14 2001-07-19 Genentech, Inc. Diagnostic et traitement de troubles hepatiques inflammatoires par inhibition de la liaison de lfa-1 a icam-1
CA2417432C (fr) * 2000-09-01 2010-11-02 The Center For Blood Research, Inc. Polypeptides modifies stabilises dans une conformation souhaitee et procedes de production correspondants
WO2002057428A1 (fr) 2000-10-30 2002-07-25 University Of Massachusetts Isolation de cellules du type spore a partir de tissus exposes a des conditions extremes
CA2473144C (fr) 2002-02-05 2013-05-28 Genentech, Inc. Purification de proteines
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
EP2277532A1 (fr) 2002-09-11 2011-01-26 Genentech, Inc. Nouvelles compositions et procédés pour le traitement de maladies liées au système immunitaire
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
EP1631590B1 (fr) * 2003-04-23 2011-07-27 Medarex, Inc. Anticorps humanises du recepteur 1 alpha d'interferon (ifnar-1)
HUE029951T2 (en) 2003-07-28 2017-04-28 Genentech Inc Reduction of Protein A Dissolution in Protein A Affinity Chromatography
CA2555820C (fr) 2004-02-19 2016-01-19 Genentech, Inc. Anticorps a regions hypervariables reparees
AU2005215024B2 (en) * 2004-02-19 2011-07-21 Dyax Corp. Conformation specific antibodies
WO2005123777A2 (fr) * 2004-06-09 2005-12-29 Genentech, Inc. Procede de traitement du granulome annulaire ou sarcoide
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (fr) 2006-12-21 2008-07-03 Millipore Corporation Purification de protéines
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
JP5361738B2 (ja) 2007-01-22 2013-12-04 ジェネンテック， インコーポレイテッド 多価電解質沈殿物及びタンパク質の精製
HUE037162T2 (hu) 2007-07-09 2018-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
CN105315323A (zh) 2007-10-30 2016-02-10 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
EP3208612B1 (fr) 2008-04-09 2019-09-18 Genentech, Inc. Compositions et procédés pour le traitement de maladies liées au système immunitaire
WO2009151514A1 (fr) 2008-06-11 2009-12-17 Millipore Corporation Bioréacteur à cuve agitée
EP2145901B1 (fr) 2008-07-18 2012-11-14 Technische Universität Braunschweig Anticorps recombinants anti-MUC1
ES2978373T3 (es) 2008-08-14 2024-09-11 Genentech Inc Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas indígenas
MX2011002372A (es) 2008-09-10 2011-04-04 Genentech Inc Composiciones y metodos para la prevencion de la degradacion oxidativa de proteinas.
SG171764A1 (en) 2008-12-16 2011-07-28 Millipore Corp Purification of proteins
US20100190963A1 (en) 2008-12-16 2010-07-29 Millipore Corporation Stirred Tank Reactor And Method
SG173812A1 (en) 2009-02-27 2011-09-29 Genentech Inc Methods and compositions for protein labelling
WO2011019619A1 (fr) 2009-08-11 2011-02-17 Genentech, Inc. Production de protéines dans des milieux de culture cellulaire sans glutamine
EP3736338A1 (fr) 2009-09-01 2020-11-11 F. Hoffmann-La Roche AG Purification améliorée d'une protéine grâce à une élution modifiée de la protéine a
AU2010319502B2 (en) 2009-11-12 2014-06-12 Vcell Therapeutics, Inc. Subpopulations of spore-like cells and uses thereof
EP2531592A1 (fr) 2010-02-04 2012-12-12 Vivalis Procédé à alimentation discontinue utilisant un milieu de culture de cellules concentré pour la production efficace de produits biologiques dans des cellules eb66
CA2792125C (fr) 2010-03-22 2019-02-12 Genentech, Inc. Compositions et procedes utiles pour stabiliser les formulations contenant des proteines
CN102958538A (zh) 2010-05-03 2013-03-06 弗·哈夫曼-拉罗切有限公司 用于降低含有蛋白质的制剂的粘度的组合物和方法
EP2571903B1 (fr) 2010-05-17 2019-09-04 EMD Millipore Corporation Polymères répondant à des stimuli pour la purification de biomolécules
WO2011150241A2 (fr) 2010-05-28 2011-12-01 Genentech, Inc. Réduction du niveau de lactate et augmentation de la production de polypeptides par régulation négative de l'expression de la lactate déshydrogénase et de la pyruvate déshydrogénase kinase
MY184736A (en) 2010-06-24 2021-04-20 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
WO2012030512A1 (fr) 2010-09-03 2012-03-08 Percivia Llc. Procédé de purification de protéine en flux
US9814740B2 (en) * 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
WO2012095514A1 (fr) 2011-01-14 2012-07-19 Vivalis Système de production de protéines recombinantes
US10364268B2 (en) 2011-12-22 2019-07-30 Genentech, Inc. Ion exchange membrane chromatography
RU2017139267A (ru) 2012-03-27 2019-02-12 Дженентек, Инк. Усовершенствованные способы выделения рекомбинантных белков
PL2849723T3 (pl) 2012-05-18 2018-10-31 Genentech, Inc. Formulacje o wysokim stężeniu przeciwciał monoklonalnych
EP2934602B1 (fr) 2012-12-19 2019-02-27 Genentech, Inc. Procédés et compositions pour le marquage de protéines par un radiohalogène
WO2015006507A1 (fr) 2013-07-09 2015-01-15 Annexon, Inc. Méthodes permettant de traiter la maladie d'alzheimer et la maladie de huntington
TWI888366B (zh) 2013-07-16 2025-07-01 美商建南德克公司 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
WO2016007752A1 (fr) 2014-07-09 2016-01-14 Genentech, Inc. Réglage de ph pour améliorer la récupération par décongélation de banques de cellules
ES3013108T3 (en) 2014-11-05 2025-04-11 Annexon Inc Humanized anti-complement factor c1q antibodies and uses thereof
EP3344658B1 (fr) 2015-09-02 2022-05-11 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Anticoprs anti tigit (human t-cell immunoglobulin and itim domain)
PH12022553648A1 (en) 2015-09-25 2024-03-11 Genentech Inc Anti-tigit antibodies and methods of use
CN115260310B (zh) 2015-11-24 2025-02-25 安尼艾克松股份有限公司 抗补体因子c1q的fab片段及其应用
CN109312299A (zh) 2016-03-29 2019-02-05 格尔托公司 蛋白质在具有0.5:1至10:1的周质体积与细胞质体积比的革兰氏阴性菌中的表达
KR102579836B1 (ko) 2016-12-22 2023-09-15 제넨테크, 인크. 동결건조된 폴리펩타이드의 재구성 시간을 감소시키기 위한 방법 및 제제
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
RS65472B1 (sr) 2018-07-03 2024-05-31 Bristol Myers Squibb Co Postupak proizvodnje rekombinantnih proteina
US12415980B2 (en) 2018-10-10 2025-09-16 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
AU2020254582B2 (en) 2019-04-01 2025-12-18 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
TW202104254A (zh) 2019-04-12 2021-02-01 美商格爾托公司 重組彈性蛋白及其生產
EP4007808A1 (fr) 2019-08-01 2022-06-08 Bristol-Myers Squibb Company Procédés d'amélioration de la productivité de protéines dans des cultures cellulaires à alimentation discontinue
US12486525B2 (en) 2020-09-22 2025-12-02 Bristol-Myers Squibb Company Methods for increasing productivity of therapeutic proteins
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
WO2023114763A1 (fr) 2021-12-13 2023-06-22 Annexon, Inc. Anticorps anti-facteur du complément c1q à bras de liaison uniques et leurs utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life

Also Published As

Publication number Publication date
FR04C0028I1 (fr) 2005-02-11
EP0941344B1 (fr) 2004-05-19
DE69729209D1 (de) 2004-06-24
PT941344E (pt) 2004-10-29
ES2221045T3 (es) 2004-12-16
IL175583A0 (en) 2006-09-05
EP1516629A2 (fr) 2005-03-23
AU4992997A (en) 1998-06-22
DE69729209T2 (de) 2005-05-19
FR04C0028I2 (fr) 2007-10-26
WO1998023761A1 (fr) 1998-06-04
KR100532178B1 (ko) 2005-12-01
EP1516629A3 (fr) 2006-09-27
DE122004000047I2 (de) 2006-06-14
EP1516629B1 (fr) 2013-04-03
CA2272842A1 (fr) 1998-06-04
DE122004000047I1 (de) 2005-04-21
ATE267257T1 (de) 2004-06-15
LU91122I2 (fr) 2005-01-10
JP4309383B2 (ja) 2009-08-05
NL300163I2 (nl) 2005-07-01
JP3778945B2 (ja) 2006-05-24
ZA979599B (en) 1999-04-28
NL300163I1 (nl) 2005-01-03
AU731817B2 (en) 2001-04-05
AU731817C (en) 2001-11-01
DK0941344T3 (da) 2004-09-27
CA2272842C (fr) 2012-05-15
JP2001505425A (ja) 2001-04-24
JP2006036779A (ja) 2006-02-09
DK1516629T3 (da) 2013-06-03
KR20000069147A (ko) 2000-11-25
IL130143A (en) 2006-08-01
EP0941344A1 (fr) 1999-09-15
AR008919A1 (es) 2000-02-23

Similar Documents

Publication Publication Date Title
ZA979599B (en) Humanized anti-CD11a antibodies
IL128406A0 (en) Monoclonal antibodies
GB9603256D0 (en) Antibodies
GB9422383D0 (en) Antibodies
PL311926A1 (en) Anti-alphav-integrinic monoclonal antibodies
ZA979185B (en) Anti-ErbB2 antibodies
PT837927E (pt) Anticorpos contra cd80
PL330111A1 (en) Concentyratyed antibody preparation
GB9809839D0 (en) Antibody
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
GB9412166D0 (en) Retargetting antibodies
HUP9800744A3 (en) Antibodies against fas-antigene
SG47153A1 (en) Benzisothiazolyi-substituted aminomethylchromans
GB9718911D0 (en) Monoclonal antibodies
GB9818915D0 (en) Antibodies
HUP9901579A3 (en) Antibodies specific for alpha-d-integrin
GB9828700D0 (en) Antibody
GB9819411D0 (en) Antibodies
GB9710820D0 (en) Immunological method
GB9615027D0 (en) Monoclonal antibodies
GB9516137D0 (en) Antibodies
GB9406243D0 (en) Antibodies
GB9406222D0 (en) Huminised antibodies
IL134049A0 (en) Anti-cryptdin antibodies
GB9415331D0 (en) Antibodies

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed